Last updated on June 2020

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer


Brief description of study

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

Clinical Study Identifier: NCT03898791

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.